Inari Medical shares are trading higher after the company reported better-than-expected Q3 sales results and raised its FY24 revenue guidance above estimates. Also, Piper Sandler maintained a Neutral rating on the stock and raised its price target from $50 to $52.
Portfolio Pulse from Benzinga Newsdesk
Inari Medical shares rose after the company reported strong Q3 sales and increased its FY24 revenue guidance. Piper Sandler maintained a Neutral rating but raised the price target from $50 to $52.
October 29, 2024 | 11:47 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Inari Medical's stock is trading higher due to better-than-expected Q3 sales and an increase in FY24 revenue guidance. Piper Sandler raised its price target to $52.
The positive Q3 sales results and increased FY24 revenue guidance are likely to boost investor confidence, leading to a rise in stock price. Piper Sandler's increased price target further supports a positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100